This device, developed in conjunction with a specialist in synthetic bone substitutes, aims to promote bone growth and thus to make vertebral fusion safer.
“This bone substitute is an ideal fit for the Walnut cage,” commented Dr. Antonio Faundez, orthopedic surgeon at the Hôpital de La Tour Geneva-Meyrin hospital in Switzerland and a member of Safe Orthopaedics’ Scientific Advisory Board. “It dovetails perfectly with Safe Orthopaedics’ strategy of offering effective solutions, while providing the surgeon with flexibility in how to use it.”
In parallel, the SteriSpineCC range (Walnut cage and associated single-use ancillary) has also received (510k) marketing approval from the US Food and Drug Administration (FDA). Although it is not commercialized in the United States, this technology will gain more rapid approval in certain countries such as in Latin America and the Asia-Pacific region.
Pierre Dumouchel, CEO of Safe Orthopaedics, added: “This bone substitute will help us to meet growing demand from surgeons, and we are delighted to be able to offer it in conjunction with our Walnut cervical cage.”